New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra)

Cotter, Jill; Wooltorton, Eric
May 2005
CMAJ: Canadian Medical Association Journal;5/10/2005, Vol. 172 Issue 10, p1299
Academic Journal
Presents a study which investigated cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. Degree of inhibition of cyclooxygenase 2 relative to cyclooxygenase 1 for various nonsteroidal anti-inflammatory agents; Advice on the use of celecoxib.


Related Articles

  • Renal effects of cyclooxygenase inhibitors in volume-depleted dogs. Brooks, David P.; Adams, Jerry; DePalma, P. Dennis; Webb, Edward F.; Palmer, Robert H.; Griswold, Don E. // Inflammopharmacology;2000, Vol. 8 Issue 1, p69 

    Objective: The objective of this study was to investigate the renal effects of celecoxib, a cyclooxygenase-2 (COX-2) specific nonsteroidal anti-inflammatory drug (NSAID). Subjects and treatment: Six volume-depleted, conscious, chronically instrumented dogs received four treatments using a...

  • Celecoxib and rofecoxib. Moore, Paul A.; Hersh, Elliot V. // Journal of the American Dental Association (JADA);Apr2001, Vol. 132 Issue 4, p451 

    Reports on the development of the nonsteroidal anti-inflammatory drugs (NSAID), celecoxib and rofecoxib, to limit the adverse effects seen after chronic use of NSAID. Cyclo-oxygenase mechanism; Specific cyclo-oxygenase 2 inhibitors; Decrease in the antihypertensive effects of...

  • Celecoxib. O'Rourke, Maureen E. // Clinical Journal of Oncology Nursing;May/Jun2000, Vol. 4 Issue 3, p143 

    Provides information on Celecoxib, a nonsteroidal anti-inflammatory drug and a cyclooxygenase-2-inhibitor. Indications of the drug; Effect of the drug on blood count; Precautions for the drug.

  • Coxib medications to be handled with care. Misak, Aleksandra // CMAJ: Canadian Medical Association Journal;2/1/2005, Vol. 172 Issue 3, p330 

    Discusses the health risks of coxib medications or the cyclooxygenase-2 (COX-2) inhibitors. Increase in the risk of myocardial infarction and cerebrovascular accident in patients taking celecoxib; Indication of COX-2 inhibitors; Logic of using COX-2 inhibitors as a replacement for nonsteroidal...

  • COX-2 inhibitor drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p201 

    An encyclopedia entry for "COX-2 inhibitor drugs" is presented. They refer to a group of nonsteroidal anti-inflammatory drugs (NSAIDs) which are less likely to cause stomach irritation. Celecoxib is one example of a COX-2 inhibitor drug.

  • Study evaluates aspirin comedication rates among long-term COX-2 inhibitor users.  // Formulary;Sep2004, Vol. 39 Issue 9, p434 

    Evaluates aspirin comedication rates among long-term COX-2 inhibitor users. Lack of difference in gastrointestinal infection ulcer complication rates between celecoxib and nonselective NSAID; Percentage of comedication with over-the-counter pain relievers.

  • COX-2 controversy: where are we and where do we go from here? Khanna, Dinesh; Khanna, Puja P.; Furst, Daniel E. // Inflammopharmacology;2005, Vol. 13 Issue 4, p395 

    Much has been written in the last few months on the association between the cyclooxygenase-2 (COX-2)-selective inhibitors and cardiovascular events. We summarize the randomized controlled studies of different COX-2 inhibitors that led to rofecoxib withdrawal, provide evidence on the differences...

  • The murky waters of the coxibs: a review of the current state of play. Ostor, Andrew J. K.; Hazleman, Brian L. // Inflammopharmacology;2005, Vol. 13 Issue 4, p371 

    Since their development and licencing no class of drug has received as much attention both in the scientific and lay press as the cyclo-oxygenase 2 (COX-2) inhibitors. These compounds, also known as coxibs, were developed as a safer alternative to traditional non-steroidal anti-inflammatory...

  • Introduction � The coxib controversies. Rainsford, K. D. // Inflammopharmacology;2005, Vol. 13 Issue 4, p331 

    Much concern has arisen in the past year concerning the occurrence of serious cardiovascular adverse reactions from rofecoxib, celecoxib and some other members of the coxib group of NSAIDs. Factors underlying the sudden appearance of these events have been proposed to include the use of high...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics